BAIT

TP53

BCC7, LFS1, P53, TRP53
tumor protein p53
GO Process (61)
GO Function (25)
GO Component (14)

Gene Ontology Biological Process

Homo sapiens
PREY

C16ORF59

chromosome 16 open reading frame 59
GO Process (0)
GO Function (0)
GO Component (0)
Homo sapiens

Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

Publication

Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.

Liu C, Banister CE, Buckhaults PJ

TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA-approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineered TP53 deletion by genome editing. We identified 27 cancer therapeutic drugs for which TP53 mutations conferred resistance; ... [more]

Cancer Res Dec. 01, 2018; 79(9);2392-2403 [Pubmed: 30862715]

Throughput

  • Low Throughput

Additional Notes

  • CRISPR GI screen
  • Cell Line: hESC
  • Experimental Setup: Drug Exposure: Cisplatin CHEBI:27899
  • GIST: Mono-phenotypic suppressing genetic interaction
  • KO of hit genes re-sensitizes TP53 KO cells to cisplatin
  • Library: GeckoV2
  • Significance Threshold: p<0.01

Curated By

  • BioGRID